Anti-tumour activity of the epipodophyllin derivative VP16–213 (etoposide: NSC-141540) in gestational choriocarcinoma
- 31 March 1980
- journal article
- Published by Elsevier BV in European Journal of Cancer (1965)
- Vol. 16 (3), 401-405
- https://doi.org/10.1016/0014-2964(80)90359-x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- VP16-213 as a single agent in advanced testicular tumorsEuropean Journal of Cancer (1965), 1980
- EPIPODOPHYLLIN DERIVATIVE (VP 16-213) IN MALIGNANT TERATOMAS AND CHORIOCARCINOMASThe Lancet, 1977
- VM 26 and VP 16–213: A comparative analysisCancer, 1977
- Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cellsBiochemistry, 1976
- Risk and prognostic factors in trophoblastic neoplasiaCancer, 1976
- A rapid, sensitive and specific radioimmunoassay for human chorionic gonadotrophinJournal of Immunological Methods, 1976
- Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.BMJ, 1975
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia--Haematosarcoma and Solid TumoursBMJ, 1973
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsEuropean Journal of Cancer (1965), 1973